LMNL News and Press, Liminal Biosciences Inc From 03/17/22

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results Canada NewsWire Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Rep...

Disclosing pharmacokinetic (PK) data from an early-stage trial for its lead asset, fezagepras, the clinical-stage biopharmaceutical company, Liminal BioSciences (NASDAQ:LMNL) said that it planned to run a Single Ascending Dose ("SAD") Phase 1a trial for the candidate in Q2 2022. The decision ...

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras Canada NewsWire Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Pla...

Liminal BioSciences (NASDAQ:LMNL) received a written notice from the Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1/share. In the event LMNL does not regain compliance by Aug. 31, the company may be eligible for additional time to regain compliance...

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement Canada NewsWire LAVAL, QC , and CAMBRIDGE, ENGLAND , March 7, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the race to bring a Covid-19 vaccine to the U.S. market, Pennsylvania-based biopharmaceutical company Ocugen  (NASDAQ: OCGN ) wasn’t the first. Not by a long shot. As a result, OCGN stock lost its luster...

Liminal BioSciences (NASDAQ:LMNL) repaid its debt of $39.1M to Structured Alpha in full, using cash on hand. The loan repayment terminates LMNL's creditor relationship with Structured Alpha. Early repayment resulted in total interest savings of C$9.1M. The repayment was funded with cash gener...

Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP Canada NewsWire Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termi...

Liminal BioSciences Announces Strategic Priorities For 2022 Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it ou...

Liminal BioSciences (NASDAQ:LMNL): Q3 Net loss from continuing operations, net of taxes was $9.7M Cash balance of $116.7M Press Release For further details see: Liminal BioSciences reports Q3 results